H.R. 7658 · 117th Congress · House

To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Active· Referred to the House Committee on Energy and Commerce.
Introduced
May 3, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Action Timeline

3
  1. MAY 03, 2022•IntroReferral

    Introduced in House

  2. MAY 03, 2022•IntroReferral

    Introduced in House

  3. MAY 03, 2022•IntroReferral

    Referred to the House Committee on Energy and Commerce.

Committees

1

Energy and Commerce Committee

hsif00

Referred: May 3, 2022

Active